Teva Pharmaceutical Industries Ltd. announced that, following the expiration of paediatric exclusivity for US Patent No. 4,743,450, the US Food and Drug Administration has granted final approval for the company's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's hypertension treatment Accupril (Quinapril Hydrochloride tablets, 5 mg, 10 mg, 20 mg and 40 mg.

Shipment of this product will commence shortly. Total annual sales of Quinapril HCl tablets in the US, including brand and generic sales, were approximately $150 million for the twelve months ended June 30, 2007, based on IMS sales data.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company.